COLOMBO NICOLETTA

Konstantinopoulos, P., Kim, J., Freyer, G., Lee, J., Gaba, L., Grisham, R., et al. (2025). Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. JOURNAL OF CLINICAL ONCOLOGY, 43(26), 2908-2917 [10.1200/JCO-25-00225]. Detail

Banerjee, S., Van Nieuwenhuysen, E., Aghajanian, C., D'Hondt, V., Monk, B., Clamp, A., et al. (2025). Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. JOURNAL OF CLINICAL ONCOLOGY, 43(25), 2782-2792 [10.1200/JCO-25-00112]. Detail

Harano, K., Fossati, R., Pardo, B., Galli, F., Hudson, E., Antill, Y., et al. (2025). Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial. JOURNAL OF GYNECOLOGIC ONCOLOGY, 36(4) [10.3802/jgo.2025.36.e117]. Detail

Ledermann, J., Oza, A., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., et al. (2025). Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. EUROPEAN JOURNAL OF CANCER, 225 [10.1016/j.ejca.2025.115584]. Detail

Randall, L., Xiang, Y., Matsumoto, T., Giannarelli, D., Milla, D., Lopez, K., et al. (2025). Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. GYNECOLOGIC ONCOLOGY, 199, 88-95 [10.1016/j.ygyno.2025.06.003]. Detail